Rubella virus vaccine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Rubella virus vaccine
Accession Number
DB10317
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Attenuated
Description

Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered. It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).

Synonyms
  • Rubella virus (vaccine strain ra27/3) live antigen
  • Rubella virus live antigen, A
  • Rubella virus strain wistar ra 27/3 live (attenuated) antigen
  • Rubella virus strain wistar ra 27/3 live antigen
  • Rubella virus vaccine live (wistar ra 27-3 strain)
  • Rubella virus vaccine,live
  • Rubella, live attenuated
  • Rubivirus rubella virus wistar ra 27/3 whole
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
M-M-R IIRubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus strain enders' attenuated edmonston live antigen (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousMerck Sharp & Dohme Corp.1971-04-21Not applicableUs
M-M-R IIRubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus strain enders' attenuated edmonston live antigen (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousA-S Medication Solutions1971-04-21Not applicableUs
M-M-R IIRubella virus vaccine (1000 TCID50/0.5mL) + Measles virus strain enders' attenuated edmonston live antigen (1000 TCID50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50/0.5mL)Powder, for solutionSubcutaneousMerck Ltd.1979-12-31Not applicableCanada
M-M-R IIRubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus strain enders' attenuated edmonston live antigen (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousPhysicians Total Care, Inc.1996-08-072012-06-30Us
PriorixRubella virus vaccine (103.0 CCID50/0.5mL) + Measles virus strain enders' attenuated edmonston live antigen (103.0 CCID50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (103.7 CCID50/0.5mL)Kit; Powder, for solutionIntramuscular; SubcutaneousGlaxosmithkline Inc1998-12-04Not applicableCanada
ProQuadRubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus strain enders' attenuated edmonston live antigen (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (20000 [TCID_50]/0.5mL) + Varicella Zoster Vaccine (Live/attenuated) (9772 [PFU]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousMerck Sharp & Dohme Limited2005-09-062018-08-31Us
ProQuadRubella virus vaccine (3 log10 tcid50/0.5mL) + Measles virus strain enders' attenuated edmonston live antigen (3 log10 tcid50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (4.3 log10 tcid50/0.5mL) + Varicella Zoster Vaccine (Live/attenuated) (3.99 log10 tcid50/0.5mL)Powder, for solutionSubcutaneousMerck Ltd.2014-05-09Not applicableCanada
ProQuadRubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus strain enders' attenuated edmonston live antigen (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (20000 [TCID_50]/0.5mL) + Varicella Zoster Vaccine (Live/attenuated) (9772 [PFU]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousMerck Sharp & Dohme Corp.2015-07-01Not applicableUs
International/Other Brands
Meruvax II
Categories
UNII
52202H034Z
CAS number
Not Available

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2-MethoxyethanolThe risk or severity of infection can be increased when Rubella virus vaccine is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of infection can be increased when Rubella virus vaccine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbacavirThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Abacavir.
AbataceptThe risk or severity of infection can be increased when Rubella virus vaccine is combined with Abatacept.
AbetimusThe risk or severity of infection can be increased when Rubella virus vaccine is combined with Abetimus.
ActeosideThe risk or severity of infection can be increased when Rubella virus vaccine is combined with Acteoside.
AcyclovirThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Acyclovir.
AdafosbuvirThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Adafosbuvir.
AdalimumabThe risk or severity of infection can be increased when Rubella virus vaccine is combined with Adalimumab.
AdefovirThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Adefovir.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910496
ATC Codes
J07BJ01 — Rubella, live attenuated

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2RecruitingOtherAcute fulminant liver failure / Heart Diseases / Renal Insufficiency,Chronic1
2Active Not RecruitingPreventionInfectious Diseases1
2CompletedPreventionChikungunya Virus Infections1
2CompletedPreventionDiseases Caused by Measles, Mumps, Rubella and Varicella Viruses / Measles-Mumps-Rubella-Varicella Vaccine / Mumps / Rubella / Rubeola / Varicella1
2CompletedPreventionHealthy Volunteers1
2CompletedPreventionMeningococcal Disease1
2CompletedPreventionMumps / Rubella / Rubeola / Varicella2
2CompletedPreventionRubeola1
3Active Not RecruitingPreventionMalaria Vaccines / Plasmodium Infections1
3CompletedPreventionAcellular Pertussis / Diphtheria / Diphtheria-Tetanus-aPertussis-Poliomyelitis Vaccines / Pertussis / Poliomyelitis / Tetanus1
3CompletedPreventionBacterial Infections / Virus Diseases1
3CompletedPreventionChickenpox Vaccines / Varicella1
3CompletedPreventionDiphtheria / Haemophilus Infections / Mumps / Pertussis / Poliomyelitis / Rubella / Rubeola / Tetanus / Varicella / Viral Hepatitis B1
3CompletedPreventionHaemophilus Influenza b Infections / Haemophilus Influenzae Type B / Meningococcal Infections / Neisseria Meningitidis / Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine1
3CompletedPreventionHaemophilus Influenzae Type B / Haemophilus Influenzae Type B Infection / Meningococcal Infections / Neisseria Meningitidis1
3CompletedPreventionHaemophilus Influenzae Type B / Neisseria Meningitidis1
3CompletedPreventionMeasles-Mumps-Rubella-Varicella Vaccine / Mumps / Rubella / Rubeola / Varicella1
3CompletedPreventionMeasles; Mumps; Rubella1
3CompletedPreventionMeningococcal Disease1
3CompletedPreventionMeningococcal Infections / Meningococcal Serogroup A, C, W-135, Y Diseases / Mumps / Rubella / Rubeola / Varicella1
3CompletedPreventionMeningococcal Meningitis1
3CompletedPreventionMeningococcal Meningitis / Mumps / Rubella / Rubeola / Varicella3
3CompletedPreventionMumps / Rubella / Rubeola4
3CompletedPreventionMumps / Rubella / Rubeola / Varicella12
3CompletedPreventionPapillomavirus Infections1
3CompletedPreventionVaricella3
3RecruitingPreventionHealthy Volunteers (Meningococcal Infection)3
3RecruitingPreventionMeningococcal Infections1
3RecruitingTreatmentInfections, Pneumococcal1
3TerminatedPreventionMumps / Rubella / Rubeola / Varicella1
4CompletedPreventionBCG Infection / Immune Response / Reaction - Vaccine1
4CompletedPreventionChickenpox / Hepatitis A / Mumps / Rubella / Rubeola1
4CompletedPreventionEncephalitis, Japanese B / Mumps / Rubella / Rubeola1
4CompletedPreventionHepatitis A Virus1
4CompletedPreventionMeasles Antibody Seroconversion / Rotavirus Geometric Mean Titer (GMT) / Rotavirus GMT / Rotavirus IgA Seropositivity / Rotavirus Immunoglobulin A (IgA) Seropositivity / Rubella Antibody Seroconversion1
4CompletedPreventionMumps / Rubella / Rubeola2
Not AvailableActive Not RecruitingNot AvailableMeningococcal Infections1
Not AvailableActive Not RecruitingNot AvailableRubeola1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableWithdrawnNot AvailableMumps / Rubella / Rubeola / Varicella1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for suspensionSubcutaneous
Kit; powder, for solutionIntramuscular; Subcutaneous
Powder, for solutionSubcutaneous
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:03 / Updated on November 02, 2019 02:39